Sales - Clinical Research Informer

Lilly blames slower-than-expected growth for 2024 sales miss

Bio Pharma Dive

JANUARY 14, 2025

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.

Sales

Sales Drugs

In strengthening Spravato sales, a positive sign for psychedelic drugs

Bio Pharma Dive

JULY 17, 2024

Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.

Sales

Sales Drugs

Abeona secures cash runway with $155m priority review voucher sale

Pharmaceutical Technology

MAY 13, 2025

Abeonas deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

Sales

Sales Development Drugs

Webinars

Can Your Organization Spot a Conflict Before It’s a Crisis?

How to Turn “Check-the-Box” Compliance Trainings Into Real Learning

MORE WEBINARS

Lilly shares fall as obesity drug sales miss forecasts

Bio Pharma Dive

OCTOBER 30, 2024

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter amid inventory decreases in the U.S.

Sales

Sales Drugs

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Are you currently in sales, or involved in a business that depends on strong sales results? What about the extremely competitive world of medical device sales? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC., Toastmasters Champion.

Sales

Novo boosts sales outlook on strong demand for obesity drug

Bio Pharma Dive

APRIL 13, 2023

The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.

Sales

Sales Drugs

Pharma earnings outline drug law’s looming impact on sales, development

Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales

Sales Development Drugs

Moderna shares fall amid lower sales outlook for RSV, COVID shots

Bio Pharma Dive

AUGUST 1, 2024

The biotech cited competitive pressure and “very low” expected sales in Europe for its latest guidance cut, which sent shares down by nearly 20%.

Sales

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Bio Pharma Dive

DECEMBER 22, 2021

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

Sales

Sales FDA Approval Doctor Doctors

Sarepta scraps a Duchenne drug as gene therapy sales rise

Bio Pharma Dive

NOVEMBER 7, 2024

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.

Sales

Sales Gene Therapy Gene Drugs

Bluebird bolsters balance sheet with sale of second regulatory fast pass

Bio Pharma Dive

JANUARY 6, 2023

The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.

Sales

Sales Gene Therapy Gene Development

Novo, Lilly buoyed by fast-growing GLP-1 drug sales

Bio Pharma Dive

NOVEMBER 2, 2023

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

Sales

Sales Drugs Production

Bristol Myers CAR-T sales rise, despite production problems

Bio Pharma Dive

JULY 27, 2022

A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.

Sales

Sales Production Manufacturing

GSK raises forecasts on strong vaccine, HIV drug sales

Bio Pharma Dive

MAY 1, 2024

Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.

Sales

Sales Vaccine Vaccination Drugs

Abeona sells speedy drug review voucher for $155M

Bio Pharma Dive

MAY 12, 2025

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review voucher, which companies can use to fast track drug reviews.

Drugs

Drugs Sales

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

Bio Pharma Dive

MAY 1, 2024

Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.

Sales

Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb

Bio Pharma Dive

APRIL 30, 2024

Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.

Sales

Sales Production Drugs

J&J puts focus on cancer drugs in push to reach 2025 sales target

Bio Pharma Dive

JANUARY 24, 2023

The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.

Sales

Sales Drugs

Roche targets continued growth after strong 2024 sales

Pharmaceutical Technology

JANUARY 31, 2025

Roche achieved a sales growth of 7% (3% in CHF) in 2024, citing strong demand for pharmaceutical products.

Sales

Sales Production

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Pharmaceutical Technology

MAY 2, 2024

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales

Sales Marketing Production

Novo sees Wegovy sales dip on lower price, tight supply

Bio Pharma Dive

MAY 2, 2024

First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

Sales

Sales Drugs

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue

Pharmaceutical Technology

AUGUST 9, 2024

Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.

Sales

Sales Drugs

When a New Drug Fails at Launch: Who’s Most to Blame?

World of DTC Marketing

JUNE 18, 2025

However, Medical Affairs people are often limited by budgets because management prefers to invest more in marketing and sales people. Sales Leadership: Overpromised, Underprepared While sales reps often get blamed for a poor launch, the real issue usually lies with sales leadership. Did they hire the right people?

Drugs

Drugs Branding Sales Marketing

Sarepta reveals lower Elevidys sales, but points to ‘massive’ opportunity ahead

Bio Pharma Dive

AUGUST 8, 2024

Company executives claimed “unprecedented demand” for the Duchenne gene therapy will soon cause a sales surge, countering a dip in quarterly sales and financial projections that raised concerns among investors.

Sales

Sales Gene Therapy Gene

Magenta to explore sale, merger after study setback

Bio Pharma Dive

FEBRUARY 3, 2023

The biotech recently stopped a trial of its experimental conditioning regimen over safety concerns. Now it’s halting further development work as it undertakes a strategic review.

Sales

Sales Trials Development

Jan Aushadhi Kendras report 6.7 per cent growth in sales in August

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 2, 2024

per cent growth in sales of generic medicines at Maximum Retail Price (MRP) value in the month of August, as compared to the sales same month a year […]

Sales

Sales Medicine Clinical Trials Clinical Trials

‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033

Pharmaceutical Technology

JUNE 5, 2025

Regeneron and Sanofis blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the pipeline.

Marketing

Marketing Sales

Gilead, fueled by latest approval, sees CAR-T sales take off

Bio Pharma Dive

OCTOBER 28, 2022

After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and Johnson & Johnson.

Sales

Sales Development

Yumanity cutting 60% of employees as it mulls possible sale

Bio Pharma Dive

FEBRUARY 17, 2022

The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program.

Sales

Sales Drugs

Nestle gives up on peanut allergy treatment after sluggish sales

Bio Pharma Dive

SEPTEMBER 5, 2023

The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

Allergies

Allergies Sales FDA Approval

Acorda files for bankruptcy, reveals asset sale plan

Bio Pharma Dive

APRIL 2, 2024

Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

Sales

Sales Marketing Drugs

Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck

Bio Pharma Dive

SEPTEMBER 30, 2021

The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts.

Sales

Sales Drugs

Novo obesity drug sales lag as manufacturing problems persist

Bio Pharma Dive

NOVEMBER 2, 2022

Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.

Manufacturing

Manufacturing Sales Medicine Drugs

Madrigal’s MASH drug sales again top Wall Street projections

Bio Pharma Dive

MAY 1, 2025

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and continuing a faster-than-expected drug launch.

Sales

Sales Drugs

Novo shares tumble on lower-than-expected obesity drug sales

Bio Pharma Dive

AUGUST 7, 2024

Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.

Sales

Sales Drugs Marketing

BioMarin preaches patience amid slow sales for hemophilia gene therapy

Bio Pharma Dive

FEBRUARY 23, 2024

The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

Gene Therapy

Gene Therapy Sales Gene

Coherus sets steep discount for Humira copycat, plans direct sales

Bio Pharma Dive

JUNE 1, 2023

The biotech will price its biosimilar Yusimry at 85% below Humira’s list price when it launches next month, and charge even less if bought through Mark Cuban’s pharmacy.

Sales

Sales Pharmacy

2seventy slims down with sale of hemophilia assets to Novo

Bio Pharma Dive

JUNE 27, 2024

Novo will pay $38 million in cash under the deal, which will also see 2seventy employees working on the program transfer to the Danish drugmaker.

Sales

How Roche plans to fill a projected $8B sales gap

Bio Pharma Dive

OCTOBER 2, 2024

Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.

Sales

Novartis sales of Zolgensma gene therapy slow as market shifts

Bio Pharma Dive

OCTOBER 25, 2022

Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.

Gene Therapy

Gene Therapy Sales Gene Marketing

ProQR sale of eye drugs comes undone over employment contracts

Bio Pharma Dive

SEPTEMBER 27, 2023

Laboratoires Théa terminated its planned purchase of ProQR’s sepofarsen after certain ProQR personnel opted against working for the French company.

Sales

Sales Drugs

Lilly sales of new diabetes drug accelerate on rising patient demand

Bio Pharma Dive

NOVEMBER 1, 2022

Company executives highlighted the “viral nature” of demand for Mounjaro, which was approved in May for diabetes and has also shown a strong weight-loss benefit in clinical testing.

Sales

Sales Drugs

Lexicon to disband sales team, lay off 60% of staff

Bio Pharma Dive

NOVEMBER 22, 2024

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.

Sales

Sales Drugs

DoP to frame ‘Disposal Policy’ for safe removal of unused and expired drugs from household & sale premises

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 10, 2024

In order to avoid environmental hazards due to pharmaceutical products, the Department of Pharmaceuticals (DoP) is thinking of framing a ‘Disposal Policy’ for removing the unused and date-expired drugs from the sale premises and from the households.

Sales

Sales Drugs Production Clinical Trials

Lilly blames slower-than-expected growth for 2024 sales miss

In strengthening Spravato sales, a positive sign for psychedelic drugs

Webinars

Trending Sources

Abeona secures cash runway with $155m priority review voucher sale

Webinars

Lilly shares fall as obesity drug sales miss forecasts

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Novo boosts sales outlook on strong demand for obesity drug

Pharma earnings outline drug law’s looming impact on sales, development

Moderna shares fall amid lower sales outlook for RSV, COVID shots

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Sarepta scraps a Duchenne drug as gene therapy sales rise

Bluebird bolsters balance sheet with sale of second regulatory fast pass

Novo, Lilly buoyed by fast-growing GLP-1 drug sales

Bristol Myers CAR-T sales rise, despite production problems

GSK raises forecasts on strong vaccine, HIV drug sales

Abeona sells speedy drug review voucher for $155M

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb

J&J puts focus on cancer drugs in push to reach 2025 sales target

Roche targets continued growth after strong 2024 sales

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Novo sees Wegovy sales dip on lower price, tight supply

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue

When a New Drug Fails at Launch: Who’s Most to Blame?

Sarepta reveals lower Elevidys sales, but points to ‘massive’ opportunity ahead

Magenta to explore sale, merger after study setback

Jan Aushadhi Kendras report 6.7 per cent growth in sales in August

‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033

Gilead, fueled by latest approval, sees CAR-T sales take off

Yumanity cutting 60% of employees as it mulls possible sale

Nestle gives up on peanut allergy treatment after sluggish sales

Acorda files for bankruptcy, reveals asset sale plan

Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck

Novo obesity drug sales lag as manufacturing problems persist

Madrigal’s MASH drug sales again top Wall Street projections

Novo shares tumble on lower-than-expected obesity drug sales

BioMarin preaches patience amid slow sales for hemophilia gene therapy

Coherus sets steep discount for Humira copycat, plans direct sales

2seventy slims down with sale of hemophilia assets to Novo

How Roche plans to fill a projected $8B sales gap

Novartis sales of Zolgensma gene therapy slow as market shifts

ProQR sale of eye drugs comes undone over employment contracts

Lilly sales of new diabetes drug accelerate on rising patient demand

Lexicon to disband sales team, lay off 60% of staff

DoP to frame ‘Disposal Policy’ for safe removal of unused and expired drugs from household & sale premises

Stay Connected